Publicacións en colaboración con investigadores/as de Complejo Asistencial Universitario de Burgos (58)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

  2. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

    Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851

  3. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry

    Cancer, Vol. 130, Núm. 20, pp. 3436-3451

  4. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice

    Blood, Vol. 144, Núm. 6, pp. 646-656

  5. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

  6. Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience

    Annals of Hematology, Vol. 103, Núm. 2, pp. 451-461

  7. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

  8. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

  9. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia

    Leukemia

  10. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

    American Journal of Hematology

2023

  1. Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia

    HemaSphere, Vol. 7, Núm. 8, pp. E936

  2. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

    Annals of Hematology, Vol. 102, Núm. 2, pp. 429-437

  3. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

    HemaSphere, Vol. 7, Núm. 1, pp. E818

  4. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

    International Journal of Antimicrobial Agents, Vol. 62, Núm. 4

  5. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

    Journal of hematology & oncology

  6. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

    Journal of Clinical Medicine, Vol. 12, Núm. 20

  7. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

    Cancers, Vol. 14, Núm. 9

  2. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 11

  3. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2231-2239